Physician profile
Tina Hackney
NPI 1306997218
$4,577.62
in general payments reported to CMS, 2019-2025
26 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $255 · 2023: $391 · 2024: $2,114 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,766 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.46 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $712.14 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $574.45 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $558.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $434.44 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Scpharmaceuticals INC. | $417.07 | 2023-2025 | |
| Novo Nordisk INC | $273.87 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.74 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.61 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $164.04 | 2024-2025 | Onpattro |
| Abiomed | $161.47 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $103.99 | 2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $93.56 | 2023-2024 | Inpefa |
| Pfizer INC. | $92.21 | 2022-2025 | |
| Cvrx, INC. | $89.35 | 2022-2024 | Barostim Neo System |
| United Therapeutics Corporation | $75.39 | 2024-2025 | Tyvaso, Tyvaso |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.59 | 2025 | |
| Celgene Corporation | $57.54 | 2024 | Camzyos |
| E.R. Squibb & Sons, L.L.C. | $54.86 | 2022-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $47.21 | 2023-2024 | Optimizer, Optimizer |
| Abbott Laboratories | $36.13 | 2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cashflow Solutions, LLC | $26.49 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Bridgebio Pharma, INC. | $19.60 | 2025 | Attruby |
| Amgen INC. | $16.46 | 2025 | Repatha |
| Lilly USA, LLC | $15.62 | 2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $15.45 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $14.02 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Hackney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.